BioXcel Therapeutics, Inc. (BTAI) is up 156.94 percent, rising $3.39 to trade at $4.44 during Monday's trading after the company announced that the FDA has closed its inspection of a site involved in the TRANQUILITY II Phase 3 trial and issued an Establishment Inspection Report with a Voluntary Action Indicated designation.
The stock opened at $2.37 and has traded between $2.37 and $6.82 today. Volume has soared to 120.23 million shares, significantly above its average of 1.91 million. BioXcel's 52-week range is $1.72 to $52.80.
This report, combined with positive findings from an independent audit in October 2023, further supports the integrity of the trial data and the clinical evidence expected for a potential supplemental New Drug Application.
BioXcel also received FDA feedback on the protocol for its TRANQUILITY In-care Phase 3 trial and plans to advance the program with its lead asset, BXCL50.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.